EDIT
NASDAQ · Biotechnology
Editas Medicine Inc
$3.24
+0.04 (+1.25%)
Open$3.19
Previous Close$3.20
Day High$3.28
Day Low$3.11
52W High$4.54
52W Low$1.66
Volume—
Avg Volume2.69M
Market Cap424.32M
P/E Ratio—
EPS$-1.22
SectorBiotechnology
Analyst Ratings
Buy
19 analysts
Price Target
+295.4% upside
Current
$3.24
$3.24
Target
$12.81
$12.81
$8.62
$12.81 avg
$14.59
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 72.02M | 56.65M | 30.54M |
| Net Income | -284,500,802 | -201,376,894 | 4.38M |
| Profit Margin | -395.0% | -375.3% | 14.4% |
| EBITDA | -275,036,371 | -205,493,159 | 9.59M |
| Free Cash Flow | — | — | 5.15M |
| Rev Growth | +27.2% | +27.2% | +16.6% |
| Debt/Equity | 2.15 | 2.15 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |